Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Mammography Approval Times Accelerate; Adoption May Take Longer

This article was originally published in The Gray Sheet

Executive Summary

Swift FDA approval of PMAs for full-field digital mammography systems, such as Hologic's LORAD, is anticipated following rapid turnaround of the Fischer SenoScan system approval.

You may also be interested in...



Hologic's LORAD

Full-field digital mammography system gains FDA "approvable" status, with final approval subject to agreement on final labeling, criteria on use of the product and completion of a good manufacturing practices audit. While the first-generation system is based on charge-coupled device (CCD) technology, a second-generation system using amorphous selenium DirectRay direct-to-digital technology is under development, and a PMA supplement filing is anticipated in the first quarter of 2002 (1"The Gray Sheet" Oct. 8, 2001, p. 28)

Hologic's LORAD

Full-field digital mammography system gains FDA "approvable" status, with final approval subject to agreement on final labeling, criteria on use of the product and completion of a good manufacturing practices audit. While the first-generation system is based on charge-coupled device (CCD) technology, a second-generation system using amorphous selenium DirectRay direct-to-digital technology is under development, and a PMA supplement filing is anticipated in the first quarter of 2002 (1"The Gray Sheet" Oct. 8, 2001, p. 28)

Mammography Device Review Warrants More Statisticians On Panel - IoM

FDA's Radiological Devices Panel should include more experts in biostatistics, technology assessment and epidemiology to ensure an appropriate regulatory path for innovative breast cancer diagnostics and to eliminate the regulatory uncertainties faced by digital mammography manufacturers, the Institute of Medicine recommends in a report released March 8.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel